TQC2938 is a humanized IgG2 monoclonal antibody inhibitor that targets stimulating factor-2 (ST2). It blocks the ST2/IL-33 signaling pathway, reducing downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and levels of eosinophils and other inflammatory cells. TQC2938 is applicable for research in inflammatory diseases like asthma.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
